Metraipolis › archive › dc_4c0fed87f3d4
Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives — Europe PMC PMID:42898767
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42898767
- DOI
- 10.3389/fphar.2026.1936459
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T08:04:57.332Z
- SHA-256 of the archived text
f25a0874dfed959e404d2c2c3622648bc2dec33c04c4d01d41d8f071673eabe9- Stable URL of this page
https://metraipolis.com/documento/dc_4c0fed87f3d4
How to cite
Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives — Europe PMC PMID:42898767 — Europe PMC (en), https://europepmc.org/article/MED/42898767 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4c0fed87f3d4 (Metraipolis archive dc_4c0fed87f3d4, sha256 f25a0874dfed959e404d2c2c3622648bc2dec33c04c4d01d41d8f071673eabe9)
BibTeX
@misc{dc4c0fed87f3d4,
title = {Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives — Europe PMC PMID:42898767},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42898767},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4c0fed87f3d4; sha256 f25a0874dfed959e404d2c2c3622648bc2dec33c04c4d01d41d8f071673eabe9},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42898767. Agents can read the archived copy with the MCP tool read_document.